GenEdit Closes $26 Million Series A

<p><strong>SOUTH SAN FRANCISCO<&sol;strong> &&num;8212&semi; GenEdit&comma; Inc&period;&comma; a biotechnology company with a mission to develop curative therapies through targeted <i>in vivo <&sol;i>delivery of genetic medicines&comma; has closed a &dollar;26 million Series A financing&period; New investors Eli Lilly&comma; KTB Network&comma; Ltd&period;&comma; Company K Partners&comma; Korea Investment Partners&comma; DAYLI Partners&comma; KB Investment&comma; IMM Investment&comma; and TIMEFOLIO Asset Management&comma; join existing investors DCVC Bio&comma; SK Holdings&comma; Bow Capital&comma; and Sequoia Capital&comma; participating in the financing&period;<&sol;p>&NewLine;<p>The funding will support the development of GenEdit’s NanoGalaxy platform of non-viral&comma; non-lipid polymer nanoparticles&comma; and the selection for clinical development of therapeutic candidates targeting diseases of the nervous system&period;<&sol;p>&NewLine;<p>In addition&comma; GenEdit disclosed new <i>in vivo<&sol;i> data demonstrating tissue-selective delivery after intravenous or intrathecal administration of its polymer nanoparticles&period; This selectivity was achieved through optimization of polymer structure utilizing the NanoGalaxy platform&period; Additional data show GenEdit’s polymer nanoparticles can be dosed multiple times with functional activity of the payload maintained in each subsequent dose&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;With this financing&comma; we are exploring the universe of opportunities within GenEdit’s NanoGalaxy platform to treat serious diseases without effective treatment options&comma;” said Dr&period; Kunwoo Lee&comma; GenEdit&&num;8217&semi;s CEO and co-founder&period;<&sol;p>&NewLine;<p>GenEdit’s NanoGalaxy platform includes thousands of chemically distinct polymers&comma; each with unique properties making them amenable to targeting different tissues and cell types and carrying diverse genetic medicine payloads&period; GenEdit’s polymer nanoparticles can deliver DNA&comma; RNA&comma; or CRISPR ribonucleoprotein&comma; depending on the requirement to add&comma; delete&comma; edit&comma; or silence a gene for therapeutic effect&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;With its NanoGalaxy platform&comma; the GenEdit team has achieved impressive delivery to cells of the central nervous system and has a tunable platform to target genetic medicines to different tissue types&comma;” said Andrew Adams&comma; Vice President of New Therapeutic Modalities at Eli Lilly and GenEdit Board observer&period; &OpenCurlyDoubleQuote;Solving the delivery problem is what will truly launch genetic medicines to being an essential therapeutic modality for a wide range of diseases&period;”<&sol;p>&NewLine;